<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08088</article-id><article-id pub-id-type="doi">10.7554/eLife.08088</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Small molecule inhibition of Csk alters affinity recognition by T cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-31837"><name><surname>Manz</surname><given-names>Boryana N</given-names></name><aff><institution content-type="dept">Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Division of Rheumatology, Department of Medicine</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32903"><name><surname>Tan</surname><given-names>Ying Xim</given-names></name><aff><institution content-type="dept">Division of Cancer Genetics and Therapeutics, Laboratory of Chromatin, Epigenetics and Differentiation</institution>, <institution>Institute of Molecular and Cell Biology</institution>, <addr-line><named-content content-type="city">Singapore</named-content></addr-line>, <country>Singapore</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-39936"><name><surname>Courtney</surname><given-names>Adam</given-names></name><aff><institution content-type="dept">Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Division of Rheumatology, Department of Medicine</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-32904"><name><surname>Rutaganira</surname><given-names>Florentine</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3021"><name><surname>Palmer</surname><given-names>Ed</given-names></name><aff><institution content-type="dept">Departments of Biomedicine and Nephrology, University Hospital Basel</institution>, <institution>University of basel</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-13773"><name><surname>Shokat</surname><given-names>Kevan M</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-32902"><name><surname>Weiss</surname><given-names>Arthur</given-names></name><aff><institution content-type="dept">Rosalind Russell and Ephraim P. Engleman Rheumatology Research Center, Division of Rheumatology, Department of Medicine</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country><email>art.weiss@ucsf.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1178"><name><surname>Sakaguchi</surname><given-names>Shimon</given-names></name><role>Reviewing editor</role><aff><institution>Osaka University</institution>, <country>Japan</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>08</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e08088</elocation-id><supplementary-material><ext-link xlink:href="elife-08088-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>14</day><month>04</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>08</month><year>2015</year></date></history><permissions><copyright-statement>Â© 2015, Manz et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Manz et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>The C-terminal Src kinase (Csk), the primary negative regulator of Src-family kinases (SFK), plays a crucial role in controlling basal and inducible receptor signaling. To investigate how Csk activity regulates T cell antigen receptor (TCR) signaling, we utilized a mouse expressing mutated Csk (Csk<sup>AS</sup>) whose catalytic activity is specifically and rapidly inhibited by a small molecule. Inhibition of Csk<sup>AS</sup> during TCR stimulation led to stronger and more prolonged TCR signaling and to increased proliferation. Inhibition of Csk<sup>AS</sup> enhanced activation by weak but strictly cognate agonists. Titration of Csk inhibition revealed that a very small increase in SFK activity was sufficient to potentiate T cell responses to weak agonists. Csk plays an important role, not only in basal signaling, but also in setting the TCR signaling threshold and affinity recognition.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#AN086836, AN107127) of the University of California, San Francisco.</p></fn></fn-group></back></article>